This specialty pharmaceutical company has seen no estimate revision in the last 7 days. However, the Zacks Consensus Estimate has moved lower over the same period. This implies trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday’s rally can last.
Flamel currently holds a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Better-ranked Med-Drug stocks worth considering include Lannett Company, Inc. (LCI), Shire plc (SHPG) and Questcor Pharmaceuticals, Inc. (QCOR). All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment